2023. Molecular Docking Study For Adenosine Monophosphate-Activated Protein Kinase Agonist From Syzygium Cumini For Treatment Of Diabetes Mellitus-Type 2. Journal of Pharmaceutical Negative Results. (Jan. 2023), 1078–1085. DOI:https://doi.org/10.47750/pnr.2023.14.S02.132.